As Boehringer Ingelheim marches on with a €20 billion R&D game plan to get 15 more drugs approved in the next 7 years, it’s shedding another early-stage oncology asset for some cash.
Xynomic Pharma is committing up to $800 million for an mTORC1/2 inhibitor in the licensing deal — its second with the German pharma — but didn’t break out the upfront, milestones and potential royalties.
The biotech, which is headquartered in the US but also operates extensively in China, plans to initiate two clinical trials in the coming six to nine months: a “potentially pivotal” Phase II in breast cancer combining BI 860585 with a standard-of-care treatment, and a Phase Ib combo study of the drug with XP-102, a pan-RAF inhibitor licensed from Boehringer Ingelheim last November in a separate $502 million pact, against colorectal cancer.
In addition to exclusive worldwide rights to the drug, Xynomic is also getting a set of Phase I results that they say showed BI 860585 was well tolerated among 90 patients. The disease control rates of the monotherapy, the exemestane combo and the paclitaxel combo were 20%, 28% and 58%, respectively.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription